FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, citing increased Guillain-Barré syndrome risk.

Pfizer's management team recently announced sales and earnings expectations for 2025. An investment-bank analyst thinks Pfizer stock can shoot about 37% higher in 2025. Pfizer has raised its ...

Beata Zawrzel / NurPhoto via Getty Images Pfizer on Tuesday affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.

Pfizer's stock has underperformed, but management's focus on R&D and cost efficiencies should boost margins and free cash flow, supporting a Buy rating. Despite political headwinds, PFE's ...

Pfizer (PFE) stock is lower in Tuesday's session ... Impact the Stock Market in 2025 President Trump will have little direct impact on the stock market, but his policies, initiatives and posts ...

Pfizer ’s executive team was using Mar-a-Lago for a planning meeting over several days, the people said. While there was no scheduled meeting between Bourla and Trump, the pair were likely to interact ...

Pfizer Inc. (NYSE:PFE) will conduct an investor call on Tuesday to provide full-year 2025 financial guidance. Ahead of the call, Goldman Sachs has outlined its expectations for the guide and ...